公开(公告)号：US20230192705A1

公开(公告)日：2023-06-22

申请号：US18009277

申请日：2021-06-10

Applicant: Betta Pharmaceuticals Co., Ltd

Inventor： Bang FU ,  Zhongxin SUN ,  Xiaofeng XU ,  Wei REN ,  Yinlong LI ,  Ling LI ,  Lieming DING ,  Jiabing WANG

IPC: C07D487/04 ,  C07D487/14 ,  C07D519/00 ,  C07F9/6561 ,  C07D491/107 ,  A61P35/00 ,  A61P11/00 ,  A61P35/02

CPC classification number: C07D487/04 ,  C07D487/14 ,  C07D519/00 ,  C07F9/6561 ,  C07D491/107 ,  A61P35/00 ,  A61P11/00 ,  A61P35/02

Abstract: Provided are compounds of Formula (I), methods of using the compounds as SHP2 inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating SHP2-mediated diseases.

公开(公告)号：US20250154149A1

公开(公告)日：2025-05-15

申请号：US18839000

申请日：2023-02-14

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Xiaofeng XU ,  Xizhen SONG ,  Xintao ZHAO ,  Yan XU ,  Liang CHEN ,  Hongfei RONG ,  Zongquan LI ,  Xiangyong LIU ,  Lieming DING ,  Jiabing WANG

IPC: C07D471/04 ,  A61K31/4985 ,  A61P35/00

Abstract: The present invention relates to a pharmaceutical composition comprising a compound as shown in formula I, and use of the pharmaceutical composition in treating diseases. The present invention also relates to a method for preparing the compound as shown in formula I.

公开(公告)号：US20230391779A1

公开(公告)日：2023-12-07

申请号：US18021784

申请日：2021-08-17

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Xiaofeng XU ,  Jinheng GAO ,  Hongfei RONG ,  Xizhen SONG ,  Jie CHEN ,  Xiangyong LIU ,  Hongling SHEN ,  Jing GUO ,  Dan YAN ,  Hong LAN ,  Lieming DING ,  Jiabing WANG

IPC: C07D487/04 ,  C07D403/04 ,  C07D471/04 ,  C07D403/06 ,  C07D231/56 ,  C07D401/14 ,  C07D401/04 ,  C07D405/04 ,  C07D413/04 ,  C07D413/14 ,  C07D405/14 ,  C07D493/04 ,  C07C237/20 ,  C07D205/04 ,  A61P35/00

CPC classification number: C07D487/04 ,  A61P35/00 ,  C07D471/04 ,  C07D403/06 ,  C07D231/56 ,  C07D401/14 ,  C07D401/04 ,  C07D405/04 ,  C07D413/04 ,  C07D413/14 ,  C07D405/14 ,  C07D493/04 ,  C07C237/20 ,  C07D205/04 ,  C07D403/04

Abstract: The present invention relates to compounds of Formula (I), pharmaceutical compositions comprising such compounds and use thereof. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer.

公开(公告)号：US20230022091A1

公开(公告)日：2023-01-26

申请号：US17898258

申请日：2022-08-29

Applicant: Betta Pharmaceuticals Co., Ltd.

Inventor： Yan XU ,  Xiaofeng XU ,  Jiabing WANG ,  Lieming DING

IPC: C07D519/00 ,  C07D471/06

Abstract: The invention relates to a bromodomain inhibitor. The invention also provides compositions and formulations comprising such compounds, and methods of using and preparing such compounds.

公开(公告)号：US20210340142A1

公开(公告)日：2021-11-04

申请号：US17271410

申请日：2019-08-27

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Xiaofeng XU ,  Jiabing WANG ,  Lieming DING

IPC: C07D471/14 ,  A61P35/00

Abstract: A maleate, mesylate, benzene sulfonate, hydrochloride, phosphate, L-tartrate, L-malate, citrate, and fumarate of a compound represented by structural formula I, various crystal forms of each salt form, and a preparation method and application thereof.

公开(公告)号：US20240174681A1

公开(公告)日：2024-05-30

申请号：US17907117

申请日：2021-03-26

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Jinheng GAO ,  Xiaofeng XU ,  Liang CHEN ,  Zhongxin SUN ,  Yun ZHANG ,  Xiangyong LIU ,  Lieming DING ,  Jiabing WANG

IPC: C07D487/14 ,  A61K31/519 ,  A61P35/00

CPC classification number: C07D487/14 ,  A61K31/519 ,  A61P35/00

Abstract: The present invention relates to a crystalline form and/or maleate, phosphate, L-tartrate, and adipate of the compound represented by the structural formula I, and various crystalline forms of various salt forms, and preparation methods and applications thereof.

公开(公告)号：US20220002307A1

公开(公告)日：2022-01-06

申请号：US17280309

申请日：2019-09-26

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Jinheng GAO ,  Zhongxin SUN ,  Yun ZHANG ,  Xiaofeng XU ,  Xiangyong LIU ,  Jiabing WANG ,  Lieming DING

IPC: C07D487/14 ,  C07D471/04 ,  C07D471/14 ,  C07D491/147 ,  C07D491/22 ,  C07D495/14 ,  C07D513/14 ,  A61P35/00

Abstract: Disclosed is a compound as a fibroblast growth factor receptor 4 (FGFR4) inhibitor (as shown in formula (I)), and a pharmaceutical composition thereof and a preparation method therefor, as well as the use of same in the treatment of FGFR4-mediated diseases. The above-mentioned compounds act by participating in a number of processes, such as regulating cell proliferation, apoptosis, migration, neovascularization.

公开(公告)号：US20210130353A1

公开(公告)日：2021-05-06

申请号：US16488899

申请日：2018-02-27

Applicant: BETTA PHARMACEUTICALS CO., LTD.

Inventor： Xiaofeng XU ,  Jiabing WANG ,  Lieming DING ,  Xiangyong LIU

IPC: C07D471/14 ,  C07D519/00 ,  A61P35/00

Abstract: An azatricyclic compound (as represented by formula I) which acts as an inhibitor of fibroblast growth factor receptors (FGFR), as well as a pharmaceutical composition thereof, a preparation method, and a use therefor in the treatment of FGFR-mediated diseases. The azatricyclic compound exerts an effect by means of participating in the regulation of a plurality of processes such as cell proliferation, apoptosis, migration, neovascularization, and the like. AA %%% Formula (I).